Skip to content

No results found

To keep going please Log in.

or

By submitting my information, I agree to the Privacy Policy and Terms of Service.

To keep going please Log in.

or

By submitting my information, I agree to the Privacy Policy and Terms of Service.

To keep going please Log in.

or

By submitting my information, I agree to the Privacy Policy and Terms of Service.

To keep going please Log in.

or

By submitting my information, I agree to the Privacy Policy and Terms of Service.

GDTC CytoMed Therapeutics Limited Ordinary Shares
$1.04 0.00% 0.00
Notify me if price changes either direction
Interactive Brokers Logotype

Buy GDTC stocks now with Interactive Brokers – the most advanced investment platform

Contents
  • Performance
  • Key stats
  • Financials
  • US politician trades
Loading

Key Stats

Market cap. 12.4M
Enterprise value 7.7M
Forward PE -7.066666
PEG Ratio -7.066666
Enterprise to EBITDA -3.127
Enterprise to revenue 13.623
Price to book MRQ 2.1955194
Price to sales TTM 17.040909

Financials

Fiscal Year Ends 2024-12-31
Most Recent Quarter (MRQ) 2024-12-31
Revenue (TTM) 568.6K
EBITDA -2477285
Diluted EPS TTM -0.25
Total Cash (MRQ) 2.2M
Current ratio (MRQ) 5.807
Operating Cash Flow (TTM) -2456417

GDTC trades by the US politicians

Percentage
0% 0 sells
100% 0 buys
Amount
$0 0 sells
$0 0 buys
In the last 0 months

Recent GDTC News

Home

No results found

IMPORTANT NOTICE

Finbold is a news and information website. This Site may contain sponsored content, advertisements, and third-party materials, for which Finbold expressly disclaims any liability.

RISK WARNING: Cryptocurrencies are high-risk investments and you should not expect to be protected if something goes wrong. Don’t invest unless you’re prepared to lose all the money you invest. (Click here to learn more about cryptocurrency risks.)

By accessing this Site, you acknowledge that you understand these risks and that Finbold bears no responsibility for any losses, damages, or consequences resulting from your use of the Site or reliance on its content. Click here to learn more.